MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day Post date January 8, 2026 ← MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering → MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
